Goldman Sachs, an international investment bank, is being blown up by a big bubble

This reporter Zhou Fen Cotton reporter recently learned that Beijing asked days law firm lawyer Zhangyuanzhong alleged fraud, caused the supervision layer of high concern.　　The CSRC expects Zhangyuanzhong to provide it with details and relevant information.　　Zhangyuanzhong to the legal daily Reporter that, in addition to the Beijing Ma commissioned him to request the supervision of the investigation of the fraud, and now there are several heavy losses of the sea-mountain investors to him to submit a similar commission.　　From this, hepalink suspected of fraud escalation. Not only that, the sea of the most expensive shares in China's securities market, the largest shareholder in the world's largest investment bank Goldman Sachs. Goldman Sachs, which has recently been caught in the "fraud gate" in the United States, has long been "a powerful" in China's capital markets.　　Analysts question the Goldman Sachs ' big Hepalink bubble. Hepalink claims that "uniqueness" should provide key evidence. In its prospectus, the company has made six claims, "We have also obtained FDA certification and the EU CEP certification, but also the only one in the United States FDA certification of heparin pharmaceutical raw materials production enterprises." It is the repetition of this "uniqueness" that reveals its ability to innovate.　　But for many institutional investors, the world's leading investment bank Goldman Sachs appeared in the third largest shareholder, it seems that the company does grow, only in the inquiry process to give the price of 148 yuan per share, the first day of the IPO is higher, the highest up to 188 yuan per share. From the public offering prospectus to the listing, Hepalink has been in the media's questioning voice.　　So, Hepalink in the end is not the same as the "domestic only access to FDA-certified Heparin API production Enterprises"? Logically, hepalink only needs to explain three aspects, which is the key evidence to answer all questions: The FDA can authenticate the API, Zhangyuanzhong said, and the other companies in the domestic industry don't get the same certification.　　Regrettably, however, Hepalink has not yet clarified these three aspects. Hepalink first issued the so-called "clarification bulletin", difficult to serve the public, and held a media meeting, asking its exclusive U.S. agency to prove that its "unique" with the interests of the witnesses can not explain the problem.　　More because the FDA spokesman said that no company certification, Hepalink is not the only one to provide similar raw materials to the United States suppliers, domestic experts more blunt, in addition to Hepalink, with similar qualifications in the domestic enterprises there are several.　　In recent days, hepalink Mister How virtuous, have the talent is frequently mentioned, it seems that this can also explain the truth of its prospectus, analysts believe that, whether the use of abusive, moral law, the law of stakeholder proof, did not specify the substantive issues. Goldman's presence in the suspected sea of the bubble market people questioned from two: Before the IPO, Hepalink total assets but 1.5 billion, net assets are only 1.3 billion, after the listing, the market value of up to 70.086 billion yuan, ranked in the A-shares of the total value of 44. The founder Li Li and his wife total wealth of up to 50.4 billion yuan, one by one, China's newRichest。 Goldman Sachs, on the other hand.　　Goldman Sachs since entering China in 1994, with its huge financial resources and the light voluntarily of investment banking business, and then through the strategic layout of China's capital market, access to huge profits, and the use of the tactics of the yin ruthless has been a lot of people have been exposed to the sea, this is a huge potential return.　　Some analysts pointed out that China Airlines oil Singapore derivatives giant losses, behind the figure of Goldman Sachs, the Chinese ocean, Shenzhen, Southern Airlines, Eastern Airlines, Air China and other overseas futures exchange losses, are inseparable from Goldman Sachs this "Black Hand." The Chinese banking industry and the opportunity to kill the victory. At a time when China's state-owned banks were restructured in 2004, Goldman Sachs had issued reports denouncing China's state-owned banks.　　But the result was Goldman's acquisition of a Chinese bank-listed stake at an extremely cheap price, with ICBC listing only on the bank, which earned nearly 12 billion dollars in 4 years. Goldman Sachs has been the underwriter of several Chinese companies ' IPOs (IPO) and reaped the benefits, covet any international investment bank.　　In the past decade, China Mobile, PetroChina, BOC (Hong Kong), Ping An insurance, ZTE and other overseas listings, Goldman Sachs through the underwriting of a full pot of money, and the upcoming IPO of ABC's H-Shares, also in the early days of Goldman Sachs income in the bag. In the Western mining industry, after the listing after the previous dividend, the cost per share fell to 0.34 yuan. July 12, 2007, known as China's mining pearl and the king of the resources of the Western mining industry grandly listed, the stock price as high as 68.5 yuan.　　It is said that in the run-up to the financial crisis, the Chinese stock market in 2008, when the Avalanche, Goldman Sachs, to reduce market capitalisation and the cost of holding shares, the Western mining industry to reduce the 5% equity has been fully recovered investment, and achieved a huge return on investment of up to 974.3% of the staggering profits. Goldman's entry into China has been criticized more and more. Market personage Analysis, Goldman settled in 5 months, Hepalink is listed. Hepalink's so-called "uniqueness" is related to Goldman Sachs. And Goldman Sachs is well on its own to give the agency an incredible price in the process of inquiry. Hepalink is probably another treasure place for Goldman Sachs.